XP13512 vs. Placebo in Patients With Restless Legs Syndrome.

PHASE3CompletedINTERVENTIONAL

Enrollment

325

Participants

Timeline

Start Date

August 31, 2006

Primary Completion Date

December 31, 2007

Study Completion Date

December 31, 2007

Conditions

Restless Legs Syndrome

Interventions

DRUG

XP13512 600MG

XP13512 600MG ONCE DAILY

DRUG

XP13512 1200MG

XP13512 1200MG ONCE DAILY

DRUG

PLACEBO

PLACEBO ONCE DAILY

All Listed Sponsors

lead

XenoPort, Inc.

INDUSTRY

NCT00365352 - XP13512 vs. Placebo in Patients With Restless Legs Syndrome. | Biotech Hunter | Biotech Hunter